Tyrosine kinase inhibitors (TKIs), specifically inhibiting BCR-ABL fusion protein and triggering apoptosis and differentiation of CML cells, are used as first-line treatment for CML [2]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.